Victory Square Technologies (VST.C) entered into a new sales and distribution contract with a Brazil based medical production and supply company today, according to a press release.
The contract is for 3.7 million COVID-19 Rapid Tests from subsidiary, Victory Square Health, over the next two years, subject to ANVISA approval.
“This newly announced 3.7 million unit contract for our Covid-19 Rapid Testing kits is an important new sales agreement as we ramp up production supply to Brazil. We are confident that this order will provide the country of Brazil with critical and accurate assistance in identifying and fighting this pandemic while also generating further sales opportunities for VSH in Brazil,” said Felipe Peixoto, CEO of Victory Square Health.
Founded in 2016, VS Health’s focus is on the development of personalized medicine and technology solutions, which includes tests in support of patient care. The company’s first product, the Leishmaniasis Rapid Test, was developed with the Federal University of Minas Gerais (UFMG). Safetest has since used its subject-matter expertise to expand their antibody-based testing range to develop diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.
This agreement comes hot on the heels of a deal with Molkom Pharmaceuticals, wherein Victory Square can leverage Molkom’s relationships through South America, including a wide supply and distribution net, and also connections to retail pharmacies, hospitals and agencies at all levels of government. The company intends to use these new leads to push the 3.7 million units out through their new distribution channels to reach the appropriate people.